Biopharmaceutical company Abide Therapeutics has collaborated with Merck to develop new therapies for type 2 diabetes and metabolic diseases.

The collaboration agreement will focus on the discovery, development and commercialisation of small-molecule therapies directed against three novel targets to treat metabolic diseases, with a particular focus on type 2 diabetes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Abide Therapeutics president and CEO Dr Alan Ezekowitz said the collaboration utilises Abide’s therapeutic engine.

"We are eager to validate unique targets that we hope will lead to the development of novel therapeutics that will benefit patients with diabetes and metabolic diseases," Ezekowitz said.

"The collaboration agreement will focus on the discovery, development and commercialisation of small-molecule therapies directed against three novel targets to treat metabolic diseases, with a particular focus on type 2 diabetes."

As per the terms of the deal, Abide is eligible for an upfront payment, research funding and potential milestone payments worth $430m for three products.

See Also:

Merck gains global commercialisation rights to products resulting from the collaboration, while Abide is eligible for sales-based royalties from any such products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additional financial details relating to the collaboration have not been disclosed.

Merck Research Laboratories diabetes and metabolism senior vice president and franchise head Nancy Thornberry said diabetes and related disorders continue to represent a global, unmet medical need.

"We look forward to working with Abide on the discovery and development of important new medicines," Thornberry added.